NMRA

Neumora is a clinical-stage 'precision neuroscience' company with no product revenue in any year shown (FY2022–FY2025 revenue is blank), so there are no fundamentals to value in the traditional sense — only cash, burn, and pipeline optionality. The financials describe a company under real strain. FY2025 operating cash flow was -$206M and the net loss was -$237M, yet cash and equivalents stand at just $183M. Taken at face value that is under twelve months of runway, and the 10-K's own forward-looking language leans heavily on 'our needs for additional financing,' 'our ability to obtain additional capital,' and 'the period over which we estimate our existing cash… will be sufficient to fund our future operating expenses' — the standard tell of a company that must raise soon.

The balance sheet is deteriorating on every axis. Total assets fell 39.7% to $191M, stockholders' equity collapsed 63.8% to $104M, and total liabilities jumped 191.5% to $87.2M. Debt now totals roughly $114.5M ($54.5M long-term plus a $60.0M current portion), and that $60M current maturity lands right on top of the thin cash position. The accumulated deficit of -$1.18B and a -228% return on equity confirm this is a business that has consumed enormous capital with nothing yet commercialized. Shares outstanding already rose 12.4% year-over-year, and at a $1.67 price any further raise to plug the runway gap would be steeply dilutive to existing holders.